TABLE 3.
Performance of the Reveal AST system by antimicrobial against Sensititre and Vitek 2
| Antimicrobial | Reveal avg TTR (h) | Sensititre as reference |
Vitek 2 as reference |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of strainsa |
% Agreement (no.) |
No. of errors |
No. of strainsa |
% Agreement (no.) |
No. of errors |
||||||||||||||
| Total | S | R | I | EA | CA | mE | ME | VME | Total | S | R | I | EA | CA | mE | ME | VME | ||
| Ampicillin | 3.5 | 66 | 24 | 42 | 0 | 100 (66) | 90.9 (60) | 6 | 0 | 0 | 67 | 23 | 43 | 1 | 94.0 (63) | 89.6 (60) | 7 | 0 | 0 |
| Piperacillin | 4.6 | 101 | 61 | 23 | 17 | 97.0 (98) | 93.1 (94) | 6 | 0 | 1 | |||||||||
| Ampicillin/sulbactam | 4.6 | 86 | 49 | 16 | 21 | 98.8 (85) | 66.3 (57) | 29 | 0 | 0 | 87 | 44 | 31 | 12 | 90.8 (79) | 81.6 (71) | 16 | 0 | 0 |
| Piperacillin-tazobactam | 4.9 | 101 | 97 | 2 | 2 | 96.0 (97) | 96.0 (97) | 2 | 0 | 2 | 104 | 97 | 3 | 4 | 94.2 (98) | 93.3 (97) | 6 | 0 | 1 |
| Cefazolin | 4.2 | 86 | 69 | 17 | 0 | 94.2 (81) | 100 (86) | 0 | 0 | 0 | 88 | 68 | 17 | 3 | 97.7 (86) | 96.6 (85) | 3 | 0 | 0 |
| Cefepime | 5.2 | 101 | 84 | 17 | 0 | 92.1 (93) | 100 (101) | 0 | 0 | 0 | 104 | 86 | 17 | 1 | 90.1 (94) | 99.0 (103) | 1 | 0 | 0 |
| Cefotaxime | 4.2 | 91 | 72 | 19 | 0 | 100 (91) | 100 (91) | 0 | 0 | 0 | |||||||||
| Ceftazidime | 4.9 | 101 | 86 | 11 | 4 | 98.0 (99) | 96.0 (97) | 3 | 1 | 0 | |||||||||
| Ceftriaxone | 4.1 | 91 | 72 | 19 | 0 | 100 (91) | 100 (91) | 0 | 0 | 0 | 93 | 74 | 19 | 0 | 97.8 (91) | 100 (93) | 0 | 0 | 0 |
| Cefoxitin | 4.1 | 86 | 82 | 2 | 2 | 95.3 (82) | 88.3 (76) | 10 | 0 | 0 | |||||||||
| Aztreonam | 5.1 | 101 | 82 | 19 | 0 | 97.0 (98) | 99.0 (100) | 1 | 0 | 0 | 93 | 74 | 19 | 0 | 100 (93) | 100 (93) | 0 | 0 | 0 |
| ESBL screen | 4.4 | 85 | 68 | 17 | 0 | NA | 100 (85) | 0 | 0 | 0 | 87 | 70 | 17 | 0 | NA | 100 (87) | 0 | 0 | 0 |
| Ertapenem | 5.7 | 91 | 89 | 1 | 1 | 100 (91) | 97.8 (89) | 2 | 0 | 0 | 93 | 90 | 2 | 1 | 97.8 (91) | 96.8 (90) | 2 | 0 | 1 |
| Imipenem | 4.9 | 101 | 99 | 0 | 2 | 97.0 (98) | 97.0 (98) | 3 | 0 | ||||||||||
| Meropenem | 6.0 | 101 | 101 | 0 | 0 | 95.0 (96) | 95.0 (96) | 4 | 1 | 104 | 103 | 1 | 0 | 94.2 (98) | 94.2 (98) | 4 | 1 | 1 | |
| Amikacin | 4.3 | 101 | 101 | 0 | 0 | 100 (101) | 100 (101) | 0 | 0 | 104 | 104 | 0 | 0 | 100 (104) | 100 (104) | 0 | 0 | ||
| Gentamicin | 4.4 | 101 | 95 | 6 | 0 | 100 (101) | 99.0 (100) | 1 | 0 | 0 | 104 | 97 | 6 | 1 | 99.0 (103) | 100 (104) | 0 | 0 | 0 |
| Tobramycin | 4.5 | 101 | 96 | 5 | 0 | 100 (101) | 98.0 (99) | 2 | 0 | 0 | 104 | 96 | 4 | 4 | 100 (104) | 98 (102) | 2 | 0 | 0 |
| Ciprofloxacin | 3.9 | 101 | 80 | 21 | 0 | 98.0 (99) | 98.0 (99) | 1 | 1 | 0 | 104 | 81 | 22 | 1 | 98.1 (102) | 99.0 (103) | 0 | 1 | 0 |
| Levofloxacin | 4.1 | 101 | 80 | 21 | 0 | 98.0 (99) | 98.0 (99) | 2 | 0 | 0 | |||||||||
| Tetracycline | 4.2 | 91 | 67 | 24 | 0 | 98.9 (90) | 98.9 (90) | 0 | 1 | 0 | |||||||||
| Tigecycline | 4.2 | 91 | 91 | 0 | 0 | 100 (91) | 100 (91) | 0 | 0 | 93 | 93 | 0 | 0 | 100 (93) | 100 (93) | 0 | 0 | ||
| Nitrofurantoin | 4.4 | 91 | 81 | 3 | 7 | 98.9 (90) | 92.3 (84) | 6 | 0 | 1 | 93 | 77 | 3 | 13 | 98.9 (92) | 86.0 (80) | 13 | 0 | 0 |
| Trimethoprim/sulfa | 3.8 | 91 | 63 | 28 | 0 | 100 (91) | 98.9 (90) | 0 | 1 | 0 | 93 | 65 | 28 | 0 | 97.9 (91) | 97.9 (91) | 0 | 2 | 0 |
a
The number of strains evaluated varies by drug, with species-drug pairs exhibiting intrinsic resistance excluded from the analysis. Three strains do not have Sensititre results. The number of strains evaluated for each comparator was used as the denominator for the respective %EA and %CA calculations.